Price Alert

Veracyte Inc. (VCYT)

NASDAQ: VCYT · Real-Time Price · USD

30.06

-0.62 (-2.02%)

At close: Aug 14, 2025, 3:59 PM

-2.02% (1D)

Bid	27.5
Market Cap	2.36B
Revenue (ttm)	479.13M
Net Income (ttm)	26.34M
EPS (ttm)	0.34
PE Ratio (ttm)	88.41
Forward PE	22.09
Analyst	Buy

Ask	30.92
Volume	1,129,951
Avg. Volume (20D)	1,691,205.4
Open	30.25
Previous Close	30.68
Day's Range	29.66 - 30.60
52-Week Range	22.61 - 47.32
Beta	1.97

About VCYT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol VCYT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for VCYT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Veracyte has released their quartely earnings on Aug 6, 2025:

Revenue of $130.16M exceeds estimates by $8.99M, with 13.75% YoY growth.

EPS of 0.44 exceeds estimates by 0.19, with 46.67% YoY growth.

Next Earnings Release

Veracyte Inc. is scheduled to release its earnings on Nov 5, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

+7.04%

Veracyte shares are trading higher amid the announ... Unlock content with Pro Subscription

5 months ago

+0.46%

Veracyte shares are trading lower. The company reported Q4 financial results.

News

3 days ago · zacks.com

VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up

Veracyte Q2 earnings and revenues beat estimates, fueled by Decipher and Afirma growth, sending shares up over 15%.

1 week ago · seekingalpha.com

Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript

Veracyte, Inc. (NASDAQ:VCYT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Marc A. Stapley - CEO & Director Phillip G.

1 week ago · fool.com

Veracyte (VCYT) Q2 Revenue Jumps 14%

1 week ago · zacks.com

Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates

Veracyte (VCYT) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.3 per share a year ago.

1 week ago · businesswire.com

Veracyte Announces Second Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025. “Testin...

2 weeks ago · zacks.com

Veracyte (VCYT) Soars 7.0%: Is Further Upside Left in the Stock?

Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

4 weeks ago · businesswire.com

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter of 2025...

1 month ago · zacks.com

Should You Continue to Hold Veracyte Stock in Your Portfolio Now?

VCYT's Decipher growth and strong cash position bolster its outlook, but Biopharma headwinds and macro risks loom.

1 month ago · businesswire.com

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025.

2 months ago · businesswire.com

Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance Prostate and Bladder Cancer Resea...

Load More News